The FDA’s Center for Drug Evaluation and Research (CDER) has issued a safety labeling change for the antidepressant Prozac (Fluoxetine)
In the safety labeling change, the CDER warns that patients who are being treated with MAOIs (Monoamine Oxidase Inhibitors) such as linezolid or intravenous methylene blue are at an increased risk of developing a life-threatening adverse drug reaction known as Serotonin Syndrome.
Serotonin Syndrome occurs following therapeutic drug use, inadvertent interactions between drugs, or the recreational use of certain drugs. The symptoms of Serotonin Syndrome are specific including cognitive, autonomic, and somatic effects and may range from barely perceptible to fatal. Although, since Serotonin Syndrome is inadvertent, it is not an unpredictable drug reaction, but rather a reaction to excess serotonergic activity at the central nervous system (CNS) and peripheral serotonin receptors, found in the central and peripheral nervous system.
If you or a loved one has suffered injury or death due to a defective or dangerous pharmaceutical, you may have a right to compensation for your injuries. The Maher Law Firm and Frank Eidson Attorney At Law would like to help. We invite you to contact our trial tested dangerous drug attorneys today.